POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced an expansion of its AI-powered in-Silico drug discovery platform. The company is now integrating more methodologies, including retrosynthetic analysis, molecular... Read More

POTOMAC, MD / ACCESS Newswire / October 22, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that its project "AHA: Agentic Harmonization Assistant" has been selected as a semi-finalist in the prestigious $1 million Alzheimer's Insights AI Prize, Accelerating... Read More

POTOMAC, MD, 1734 / ACCESS Newswire / October 14, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational drug candidate IGC-AD1 for agitation in Alzheimer's disease. The trial has... Read More

POTOMAC, MARYLAND / ACCESS Newswire / October 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that during its Annual Meeting of Stockholders scheduled for and convened on October 10, 2025 (the "Annual Meeting"), all proposals as disclosed on the Definitive... Read More

IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD, 1734 / ACCESS Newswire / October 7, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced in-vitro findings for... Read More

POTOMAC, MD / ACCESS Newswire / September 29, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease. The new site, Ichor Research, located in Syracuse, New York, is led by Principal Investigator Dr. Karl F. Hafner, M.D. Dr. Hafner brings years of... Read More

POTOMAC, MD / ACCESS Newswire / September 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced preclinical findings on TGR-63, the Company's investigational small-molecule candidate for Alzheimer's disease. The data demonstrate that TGR-63 extends its therapeutic potential beyond previously reported effects on beta-amyloid (Aβ) pathology by also inhibiting tau protein aggregation, another key hallmark of... Read More

POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease. This milestone marks a significant step in advancing IGC-AD1, the... Read More

POTOMAC, MD / ACCESS Newswire / September 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced that its Artificial Intelligence (AI) team has been recognized with a special award for excellence in clean code development as part of the National Institute on Aging (NIA) PREPARE Challenge. The award highlights IGC Pharma's... Read More

POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in Alzheimer's dementia, to a new international site at Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada. "Bringing CALMA to Canada is a milestone in our mission to offer... Read More

POTOMAC, MD / ACCESS Newswire / August 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette's syndrome with THC and/or CBD. A notice of... Read More

POTOMAC, MD / ACCESS Newswire / August 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those... Read More

POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma. Dr. Carl Griffin, MD, will serve as the... Read More

POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial results for the quarter ended June 30, 2025. Highlights in the quarter include: Accelerated progress on the Company's Phase 2 CALMA trial in Alzheimer's disease Progress in... Read More

Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology POTOMAC, MARYLAND / ACCESS Newswire / August 12, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced promising preclinical results for... Read More

New hope in Alzheimer's: IGC-M3 targets the disease on four fronts, showing promise in cellular models POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today announced encouraging preclinical data on its investigational molecule... Read More

Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the presentation of three scientific posters at the 2025 Alzheimer's Association International Conference... Read More

POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D., has been awarded the Best Researcher Award at the 11th Annual World Neuroscientist Awards. Dr. Rao was selected through a rigorous evaluation by an international panel of academic and industry experts... Read More

Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's , the Company's proprietary AI-powered diagnostic... Read More

POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined Fiscal Year 2025, ended March 31, 2025. This past year has been nothing short of transformative, marked by significant... Read More

POTOMAC, MARYLAND / ACCESS Newswire / June 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company will host a conference call and webcast on Monday, June 30, 2025, at 11:00 a.m. Eastern Time to review the Company's operational progress for the fiscal year ended March 31, 2025. The Company will release its fiscal year 2025 financial results that day before the market opens.... Read More

POTOMAC, MD / ACCESS Newswire / June 23, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Oklahoma, for its Phase 2 CALMA study evaluating IGC-AD1 for agitation in Alzheimer's dementia. This expansion into the Oklahoma City metropolitan area underscores IGC's commitment to diversifying its trial population and... Read More

POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region. Approximately 12.5% of Puerto Ricans over the age... Read More

POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting , showcasing key non-clinical data that support the genetic safety profile of one of the two active... Read More

POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share Purchase Agreement (the "SPA") on April 21, 2025, for the purchase of common shares from the Company. The investment, subject to the terms and conditions set forth in the SPA, is for approximately $475 thousand at the higher of... Read More

Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of Frank Zaccanelli, Robert K. Coughlin, and Joseph Mangan to its Board of Advisors. The Advisory Board will provide strategic guidance as IGC advances its... Read More

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital's Memory and Aging Program, a nationally recognized research center affiliated with the Warren Alpert Medical School of Brown University, in Providence, Rhode Island. The site will support... Read More

POTOMAC, MARYLAND / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer's dementia, to MIND Institute at Miami Jewish Health in Miami, Florida. This addition further advances the company's efforts to accelerate the trial's completion and builds on promising interim data... Read More

IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer's disease. Based on the interim analysis at week 2... Read More

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and... Read More

POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital in St. Petersburg, Florida as part of its ongoing Phase 2 CALMA trial evaluating IGC-AD1, the Company's lead therapeutic candidate, for the treatment of agitation in Alzheimer's dementia. IGC-AD1 is a combination... Read More

POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are... Read More

POTOMAC, MARYLAND / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled " Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily... Read More

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions... Read More

New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health... Read More

POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr. Ram Mukunda, CEO. "We are also planning to... Read More

Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and sustained energy . This strategic expansion into the... Read More

POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance... Read More

POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the... Read More

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its... Read More

POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43 rd Annual Healthcare Conference 2025. Management will be available for in-person and virtual meetings. Details of the events are as follows: Event: BIO Partnering @ JPM Date: January 13 -... Read More

New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease Expanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program... Read More

Interim results indicate cognitive improvement in the active treatment group compared to placebo No serious adverse events or deaths reported in the trial POTOMAC, Md. / Nov 25, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1. The trial focuses on agitation in Alzheimer's as its... Read More

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic... Read More

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series. In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's... Read More

Company Expands Phase 2 trial to Canada POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. Agitation affects between 40-80% of... Read More

POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National... Read More

IGC-AD1 demonstrates the potential to modify tau and improve spatial memory Data supports the initiation of clinical trials investigating IGC-AD1 as a treatment for Alzheimer's disease POTOMAC, Md. / Sep 18, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced data that reinforces the therapeutic potential of IGC-AD1 as a disease-modifying treatment for Alzheimer's... Read More

POTOMAC, Md. / Sep 04, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") announced today that the Company is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer's disease. Following the FDA's 2023 approval of two groundbreaking anti-amyloid drugs, Donanemab (Eli Lilly) and Lecanemab (Eisai and... Read More

POTOMAC, Md. / Aug 26, 2024 / Business Wire / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of... Read More

IGC-1C Targets Tau Protein and GLP-1 Receptor, Offering a Multi-Pathway Approach to Neurodegenerative and Metabolic Disease Treatment POTOMAC, Md. / Aug 22, 2024 / Business Wire / IGC Pharma, Inc . (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced preclinical research demonstrating the therapeutic potential of IGC-1C, a novel small-molecule modulator. The findings show that IGC-1C targets tau protein phase... Read More

Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies POTOMAC, Md. / Aug 20, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced that the Company's proprietary molecule, IGC-1A, has been identified as a potential GLP-1 agonist, as a result of the Company's state-of-the-art Artificial Intelligence ("AI") modeling. This... Read More

POTOMAC, Md. / Aug 08, 2024 / Business Wire / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company’s Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic... Read More

POTOMAC, Md. / Jul 18, 2024 / Business Wire / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) announces that Alliance Global Partners (AGP) has issued an analyst coverage research report on the Company’s common stock. All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy,... Read More